{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:23:44Z","timestamp":1791156224846,"version":"4.1.0"},"reference-count":204,"publisher":"Elsevier","isbn-type":[{"value":"9780323988490","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acc.2021.08.002","type":"book-chapter","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:25:22Z","timestamp":1654043122000},"page":"155-209","source":"Crossref","is-referenced-by-count":12,"title":["Mono\/polyclonal free light chains as challenging biomarkers for immunological abnormalities"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2021.08.002_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0140-6736(02)86528-X","article-title":"Papers ON CHEMICAL PATHOLOGY","volume":"50","author":"Bence Jones","year":"1847","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2021.08.002_bb0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1098\/rspl.1899.0121","article-title":"On immunity with special reference to cell life","volume":"66","author":"Croonian lecture","year":"1900","journal-title":"Proc. R. Soc. Lond"},{"key":"10.1016\/bs.acc.2021.08.002_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1084\/jem.69.1.119","article-title":"An electrophoretic study of immune sera and purified antibody preparations","volume":"69","author":"Tiselius","year":"1939","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9258(18)71123-X","article-title":"Proteins in multiple myeloma. III. Origin of Bence-Jones protein","volume":"212","author":"Putnam","year":"1955","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0030","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1016\/S0021-9258(18)94320-6","article-title":"Polymeric forms of free normal kappa and lambda chains of human immunoglobulin","volume":"244","author":"Bergg\u00e5rd","year":"1969","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0035","first-page":"207","article-title":"The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins","volume":"116","author":"Edelman","year":"1962","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0040","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.180.4087.713","article-title":"Structural studies of immunoglobulins","volume":"180","author":"Porter","year":"1973","journal-title":"Science"},{"key":"10.1016\/bs.acc.2021.08.002_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM197601012940105","article-title":"Bence-Jones proteins and light chains of immunoglobulins (first of two parts)","volume":"294","author":"Solomon","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.0954-6820.1979.tb13511.x","article-title":"Free light chains of immunoglobulins in amyloidosis","volume":"206","author":"S\u00f8lling","year":"1979","journal-title":"Acta Med. Scand."},{"key":"10.1016\/bs.acc.2021.08.002_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2017.09.005","article-title":"Free light chains: eclectic multipurpose biomarker","volume":"451","author":"Basile","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/bs.acc.2021.08.002_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.genet.39.073003.110544","article-title":"Immunoglobulin gene diversification","volume":"39","author":"Maizels","year":"2005","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/bs.acc.2021.08.002_bb0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0145-305X(01)00066-0","article-title":"The mysterious immunoglobulin light chain","volume":"26","author":"Pilstr\u00f6m","year":"2002","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0070","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cca.2011.03.007","article-title":"Free immunoglobulin light chain: its biology and implications in diseases","volume":"412","author":"Nakano","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2021.08.002_bb0075","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/381751a0","article-title":"Clonal selection and learning in the antibody system","volume":"381","author":"Rajewsky","year":"1996","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2021.08.002_bb0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0076-6879(85)16008-8","article-title":"Light chains of human immunoglobulins","volume":"116","author":"Solomon","year":"1985","journal-title":"Methods Enzymol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3410\/M5-4","article-title":"Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?","volume":"5","author":"Brebner","year":"2013","journal-title":"F1000 Med. Rep."},{"key":"10.1016\/bs.acc.2021.08.002_bb0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ki.1979.128","article-title":"Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review","volume":"16","author":"Maack","year":"1979","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2021.08.002_bb0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.autrev.2019.03.003","article-title":"Free light chains and autoimmunity","volume":"18","author":"Napodano","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/bs.acc.2021.08.002_bb0100","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1373\/clinchem.2011.169433","article-title":"Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation","volume":"57","author":"Hutchison","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ijlh.12159","article-title":"The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease","volume":"36","author":"Burmeister","year":"2014","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.abb.2004.08.022","article-title":"Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain","volume":"431","author":"Boivin","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/bs.acc.2021.08.002_bb0115","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","article-title":"Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma","volume":"97","author":"Drayson","year":"2001","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/bs.acc.2021.08.002_bb0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0130","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1515\/CCLM.2011.624","article-title":"N latex FLC\u2014new monoclonal high-performance assays for the determination of free light chain kappa and lambda","volume":"49","author":"te Velthuis","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0135","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1515\/CCLM.2006.118","article-title":"Immunochemical quantification of free immunoglobulin light chains from an analytical perspective","volume":"44","author":"Nakano","year":"2006","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2006.07.011","article-title":"Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases","volume":"376","author":"Tate","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2021.08.002_bb0145","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0150","first-page":"348","article-title":"Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain \u03ba\/\u03bb ratio","volume":"40","author":"Levinson","year":"2010","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/bs.acc.2021.08.002_bb0155","doi-asserted-by":"crossref","first-page":"973","DOI":"10.21037\/atm.2020.03.200","article-title":"How to quantify monoclonal free light chains in plasma cell disorders: which mass spectrometry technology?","volume":"8","author":"Moreau","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22243","article-title":"Serum free light chain quantitative assays: dilemma of a biomarker","volume":"32","author":"Cigliana","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/bs.acc.2021.08.002_bb0165","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0170","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/ndt\/17.12.2043","article-title":"Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes?","volume":"17","author":"Viedt","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/bs.acc.2021.08.002_bb0175","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0180","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m Macroglobulinaemia: a task force from the 8th international workshop on Waldenstr\u00f6m Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0190","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.clml.2017.06.022","article-title":"Smoldering multiple myeloma: who and when to treat","volume":"17","author":"Mateos","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/bs.acc.2021.08.002_bb0195","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0200","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and management of monoclonal gammopathy of renal significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/bs.acc.2021.08.002_bb0205","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.2009.07952.x","article-title":"Frequency of altered monoclonal protein production at relapse of multiple myeloma","volume":"148","author":"Hobbs","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/bs.acc.2021.08.002_bb0220","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0225","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","article-title":"Multiple myeloma: causes and consequences of delay in diagnosis","volume":"100","author":"Kariyawasan","year":"2007","journal-title":"QJM"},{"key":"10.1016\/bs.acc.2021.08.002_bb0230","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0235","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/bs.acc.2021.08.002_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237155","article-title":"The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements","volume":"15","author":"Cedena","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2021.08.002_bb0245","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.1969.tb00441.x","article-title":"Growth rates and responses to treatment in human myelomatosis","volume":"16","author":"Hobbs","year":"1969","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00432-008-0470-7","article-title":"\u2018Light-chain escape-multiple myeloma\u2019-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring","volume":"135","author":"K\u00fchnemund","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0255","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood-2013-12-542662","article-title":"Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome","volume":"123","author":"Brioli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0260","first-page":"202","article-title":"Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets","volume":"7","author":"Steiner","year":"2014","journal-title":"Memory"},{"key":"10.1016\/bs.acc.2021.08.002_bb0265","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.acc.2021.08.002_bb0270","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2006-02-005496","article-title":"Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma","volume":"108","author":"Walker","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0275","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3324\/haematol.10297","article-title":"Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains","volume":"92","author":"Dawson","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/bs.acc.2021.08.002_bb0280","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3109\/10428194.2010.506933","article-title":"An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers","volume":"51","author":"Qu","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/bs.acc.2021.08.002_bb0285","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/bmt.2012.151","article-title":"Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients\u2019 monitoring after transplantation","volume":"48","author":"Zamarin","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/bs.acc.2021.08.002_bb0290","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.clml.2014.02.004","article-title":"Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed\/refractory multiple myeloma","volume":"14","author":"Ahn","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/bs.acc.2021.08.002_bb0295","first-page":"694730","article-title":"Aggressive FLC escape in a patient with IgD myeloma","volume":"2015","author":"Farges","year":"2015","journal-title":"Case Rep Hematol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0300","first-page":"48","article-title":"Light chain escape followed by leukemic transformation in a patient with IgD myeloma","volume":"56","author":"Hatsuse","year":"2015","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/bs.acc.2021.08.002_bb0305","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1515\/cclm-2015-0689","article-title":"New patterns of relapse in multiple myeloma: a case of \u201clight chain escape\u201d in which FLC predicted relapse earlier than urine and serum immunofixation","volume":"54","author":"Caldini","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0310","first-page":"809840","article-title":"Light chain escape in 3 cases: evidence of Intraclonal heterogeneity in multiple myeloma from a single institution in Poland","volume":"2015","author":"Kraj","year":"2015","journal-title":"Case Rep Hematol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0315","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/jclinpath-2012-200669","article-title":"Association of plasma cell subsets in the bone marrow and free light chain concentrations in the serum of monoclonal gammopathy patients","volume":"65","author":"Ayliffe","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0320","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3324\/haematol.11133","article-title":"Demonstration of changes in plasma cell subsets in multiple myeloma","volume":"92","author":"Ayliffe","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/bs.acc.2021.08.002_bb0325","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0330","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0335","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11899-018-0451-0","article-title":"Light chain cast nephropathy: practical considerations in the Management of Myeloma Kidney-What we Know and What the future may hold","volume":"13","author":"Manohar","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/bs.acc.2021.08.002_bb0340","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma","volume":"1","author":"Yadav","year":"2016","journal-title":"Kidney Dis. (Basel)."},{"key":"10.1016\/bs.acc.2021.08.002_bb0345","first-page":"4293","article-title":"A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders","volume":"23","author":"Basile","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/bs.acc.2021.08.002_bb0350","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0355","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000454","article-title":"Systemic AL amyloidosis: current approaches to diagnosis and management","volume":"4","author":"Fotiou","year":"2020","journal-title":"HemaSphere."},{"key":"10.1016\/bs.acc.2021.08.002_bb0360","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0365","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.21948","article-title":"Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis","volume":"86","author":"Kumar","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0370","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","article-title":"Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)","volume":"101","author":"Abraham","year":"2003","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2021.08.002_bb0375","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ckj\/sfu021","article-title":"Amyloid nephropathy","volume":"7","author":"Khalighi","year":"2014","journal-title":"Clin. Kidney J."},{"key":"10.1016\/bs.acc.2021.08.002_bb0380","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/labinvest.3700161","article-title":"AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells","volume":"84","author":"Keeling","year":"2004","journal-title":"Lab. Invest."},{"key":"10.1016\/bs.acc.2021.08.002_bb0385","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney","volume":"27","author":"Eirin","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/bs.acc.2021.08.002_bb0390","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/sj.ki.5002411","article-title":"Intra-tubular amyloidosis","volume":"72","author":"El-Zoghby","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2021.08.002_bb0395","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/ckj\/sfv087","article-title":"Proteomics and mass spectrometry in the diagnosis of renal amyloidosis","volume":"8","author":"Picken","year":"2015","journal-title":"Clin. Kidney J."},{"key":"10.1016\/bs.acc.2021.08.002_bb0400","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.510250122","article-title":"Hepatic amyloidosis: clinical appraisal in 77 patients","volume":"25","author":"Gertz","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/bs.acc.2021.08.002_bb0410","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/jcm8050739","article-title":"Magnetic resonance elastography of liver in light chain amyloidosis","volume":"8","author":"Venkatesh","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0415","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1681\/ASN.2008121226","article-title":"New insights into epithelial-mesenchymal transition in kidney fibrosis","volume":"21","author":"Liu","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0420","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.2215\/CJN.03350411","article-title":"Serum free light chains and the risk of ESRD and death in CKD","volume":"6","author":"Haynes","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0425","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1681\/ASN.2006111299","article-title":"Immunoglobulin light chains generate hydrogen peroxide","volume":"18","author":"Wang","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0430","doi-asserted-by":"crossref","first-page":"31607","DOI":"10.1074\/jbc.271.49.31607","article-title":"Molecular cloning and characterization of a novel protein kinase with a catalytic domain homologous to mitogen-activated protein kinase kinase kinase","volume":"271","author":"Wang","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0435","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1681\/ASN.2012040388","article-title":"Mechanisms of light chain injury along the tubular nephron","volume":"23","author":"Sanders","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0440","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.5858\/2007-131-1368-ETPSOI","article-title":"Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy","volume":"131","author":"Kapur","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0445","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneph.2009.151","article-title":"Serum free light chain assessment in monoclonal gammopathy and kidney disease","volume":"5","author":"Hutchison","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0450","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.V661592","article-title":"Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions","volume":"6","author":"Cohen","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0455","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1046\/j.1523-1755.63.s84.8.x","article-title":"Immunoglobulin light chains in uremia","volume":"84","author":"Cohen","year":"2003","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/bs.acc.2021.08.002_bb0460","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1681\/ASN.2009101089","article-title":"Immunoglobulin light chains activate tubular epithelial cells through redox signaling","volume":"21","author":"Basnayake","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0465","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2008.02.005","article-title":"IL-6 regulates MCP-1, ICAM-1 and IL-6 expression in human myoblasts","volume":"196","author":"Marino","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0470","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1471-4906(03)00112-1","article-title":"IL-6, monocyte infiltration and parenchymal cells","volume":"24","author":"Bartoccioni","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0475","first-page":"841","article-title":"Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets","volume":"27","author":"Marino","year":"2013","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/bs.acc.2021.08.002_bb0480","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/oxfordjournals.jbchem.a022660","article-title":"Upstream regions directing heart-specific expression of the GATA6 gene during mouse early development","volume":"127","author":"Sun-Wada","year":"2000","journal-title":"J. Biochem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0485","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.ki.5000212","article-title":"The relationship between albuminuria, MCP-1\/CCL2, and interstitial macrophages in chronic kidney disease","volume":"69","author":"Eardley","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2021.08.002_bb0490","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1053\/ajkd.2000.17620","article-title":"Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells","volume":"36","author":"Pote","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0495","first-page":"1153","article-title":"Urinalysis: a comprehensive review","volume":"71","author":"Simerville","year":"2005","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/bs.acc.2021.08.002_bb0500","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3390\/toxins5112058","article-title":"European uremic toxin (EUTox) work group, association between free light chain levels, and disease progression and mortality in chronic kidney disease","volume":"5","author":"Desjardins","year":"2013","journal-title":"Toxins (Basel)."},{"key":"10.1016\/bs.acc.2021.08.002_bb0505","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jclinpath-2012-200910","article-title":"Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study","volume":"65","author":"Anandram","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0510","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.mayocp.2014.01.028","article-title":"Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease","volume":"89","author":"Hutchison","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/bs.acc.2021.08.002_bb0515","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2215\/CJN.09660914","article-title":"Association of Serum Ig Free Light Chains with mortality and ESRD among patients with nondialysis-dependent CKD","volume":"10","author":"Ritchie","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0520","article-title":"The association between polyclonal combined serum free light chain concentration and mortality in individuals with early chronic kidney disease","volume":"10","author":"Assi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2021.08.002_bb0525","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00398.x","article-title":"Cholesterol and recurrent events (CARE) trial investigators, biomarkers of inflammation and progression of chronic kidney disease","volume":"68","author":"Tonelli","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2021.08.002_bb0530","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anorl.2011.03.002","article-title":"Anatomy and physiology of cerebrospinal fluid","volume":"128","author":"Sakka","year":"2011","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0535","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.expneurol.2015.07.027","article-title":"A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans","volume":"273","author":"Spector","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0540","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s00415-008-0954-z","article-title":"Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis","volume":"255","author":"Presslauer","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0545","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMp1110812","article-title":"What's the alternative? The worldwide web of integrative medicine","volume":"366","author":"Srivastava","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0550","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/1352458517711275","article-title":"Low reliability of anti-KIR4.183\u2013120 peptide auto-antibodies in multiple sclerosis patients","volume":"24","author":"Marino","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/bs.acc.2021.08.002_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2013.06.014","article-title":"Intrathecal oligoclonal IgG synthesis in multiple sclerosis","volume":"262","author":"Petzold","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0560","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5507\/bp.2014.058","article-title":"Oligoclonal free light chains in cerebrospinal fluid as markers of intrathecal inflammation. Comparison with oligoclonal IgG","volume":"159","author":"Zeman","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"issue":"3","key":"10.1016\/bs.acc.2021.08.002_bb0565","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1515\/cclm-2020-1037","article-title":"Inter-center agreement in the interpretation of oligoclonal bands","volume":"59","author":"Mariotto","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0570","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1352458515594044","article-title":"Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study","volume":"22","author":"Presslauer","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/bs.acc.2021.08.002_bb0575","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1515\/cclm-2017-0285","article-title":"Application of \u03ba free light chains in cerebrospinal fluid as a biomarker in multiple sclerosis diagnosis: development of a diagnosis algorithm","volume":"56","author":"Valencia-Vera","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0580","doi-asserted-by":"crossref","first-page":"551","DOI":"10.7754\/Clin.Lab.2016.160930","article-title":"Combined use of kappa free light chain index and Isoelectrofocusing of Cerebro-spinal fluid in diagnosing multiple sclerosis: performances and costs","volume":"63","author":"Crespi","year":"2017","journal-title":"Clin. Lab."},{"key":"10.1016\/bs.acc.2021.08.002_bb0585","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ene.14121","article-title":"Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis","volume":"27","author":"Ferraro","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0590","doi-asserted-by":"crossref","first-page":"577122","DOI":"10.1016\/j.jneuroim.2019.577122","article-title":"Kappa free light chains index in the differential diagnosis of multiple sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders","volume":"339","author":"Cavalla","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/bs.acc.2021.08.002_bb0595","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/diagnostics10100856","article-title":"Kappa index versus CSF oligoclonal bands in predicting multiple sclerosis and infectious\/inflammatory CNS disorders","volume":"10","author":"Ferraro","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/bs.acc.2021.08.002_bb0600","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1515\/cclm-2018-0028","article-title":"Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis","volume":"56","author":"Hegen","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0605","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement","volume":"62","author":"Freedman","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0610","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1515\/cclm-2019-0315","article-title":"Diagnostic performance of cerebrospinal fluid free light chains in Lyme neuroborreliosis\u2014a pilot study","volume":"57","author":"Tjernberg","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0615","doi-asserted-by":"crossref","first-page":"577108","DOI":"10.1016\/j.jneuroim.2019.577108","article-title":"Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis","volume":"339","author":"Gaetani","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0620","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2019.02.001","article-title":"Kappa free light chains could predict early disease course in multiple sclerosis","volume":"30","author":"Vecchio","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/bs.acc.2021.08.002_bb0625","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/CBF.S57681","article-title":"Polyclonal free light chains: promising new biomarkers in inflammatory disease","volume":"4","author":"Hampson","year":"2014","journal-title":"Curr. Biomark. Find."},{"key":"10.1016\/bs.acc.2021.08.002_bb0630","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1373\/clinchem.2011.169433","article-title":"Polyclonal immunoglobulin free light chains as a PotentialBiomarker of immune stimulation and inflammation","volume":"57","author":"Hutchison","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0635","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ejphar.2005.12.065","article-title":"Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases","volume":"533","author":"van der Heijden","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0640","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1172\/JCI113970","article-title":"Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages","volume":"83","author":"Savill","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2021.08.002_bb0645","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0272-6386(99)70375-6","article-title":"Neutrophils and renal failure","volume":"34","author":"Heinzelmann","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0650","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nm722","article-title":"Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses","volume":"8","author":"Redegeld","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0655","first-page":"282","article-title":"Immunoglobulin free light chains in the pathogenesis of lung disorders","volume":"16","author":"Mortaz","year":"2017","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0660","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1073\/pnas.0406808102","article-title":"Elicitation of allergic asthma by immunoglobulin free light chains","volume":"102","author":"Kraneveld","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2021.08.002_bb0665","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2011.03.028","article-title":"Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens","volume":"34","author":"Dudeck","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2021.08.002_bb0670","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1172\/JCI119218","article-title":"Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein","volume":"99","author":"Huang","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2021.08.002_bb0675","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.tips.2008.01.004","article-title":"Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases","volume":"29","author":"Thio","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/bs.acc.2021.08.002_bb0680","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A summary of the new GINA strategy: a roadmap to asthma control","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/bs.acc.2021.08.002_bb0685","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1164\/ajrccm.162.6.9912001","article-title":"Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group","volume":"162","author":"Amin","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0690","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.201104-0761OC","article-title":"An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease","volume":"185","author":"Braber","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0695","first-page":"945","article-title":"Expression and significance of immunoglobulin free light chains in serum and lung tissues from patients with chronic obstructive pulmonary disease","volume":"36","author":"Zhang","year":"2013","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/bs.acc.2021.08.002_bb0700","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.1780090508","article-title":"Increase of L-chain proteins in the sera of patients with systemic lupus erythematosus and the synovial fluids of patients with peripheral rheumatoid arthritis","volume":"9","author":"Epstein","year":"1966","journal-title":"Arthritis Rheum."},{"key":"10.1016\/bs.acc.2021.08.002_bb0705","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/ard.27.6.537","article-title":"Free immunoglobulin light chains in connective tissue diseases","volume":"27","author":"Cooper","year":"1968","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0710","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF00918666","article-title":"Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin","volume":"9","author":"Hopper","year":"1989","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0715","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1006686514743","article-title":"Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig","volume":"20","author":"Hopper","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0720","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0725","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.20446","article-title":"Serum free light chains as biomarkers for systemic lupus erythematosus disease activity","volume":"63","author":"Aggarwal","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/bs.acc.2021.08.002_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148151","article-title":"Correction: elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein-Barr virus antibodies","volume":"11","author":"Draborg","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2021.08.002_bb0735","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/0961203314530793","article-title":"Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus","volume":"23","author":"Jolly","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/bs.acc.2021.08.002_bb0740","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10067-019-04827-4","article-title":"Determination of serum free light chains as a marker of systemic lupus flare","volume":"39","author":"Cambr\u00f3n","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0745","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10067-010-1674-1","article-title":"Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity","volume":"30","author":"Chiche","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0750","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/nyas.13562","article-title":"Rituximab in myasthenia gravis: a \u201cto be or not to be\u201d inhibitor of T cell function: rituximab and T cell function","volume":"1413","author":"Marino","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.acc.2021.08.002_bb0755","first-page":"715","article-title":"Increased intrathecal immunoglobulin synthesis of both kappa and lambda types in patients with systemic lupus erythematosus and central nervous system involvement","volume":"13","author":"Hirohata","year":"1986","journal-title":"J. Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0760","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.51.2.168","article-title":"Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis","volume":"51","author":"Tsai","year":"1992","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0765","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/rheumatology\/ket108","article-title":"Urinary free light chain is a potential biomarker for ISN\/RPS class III\/IV lupus nephritis","volume":"52","author":"Hanaoka","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/bs.acc.2021.08.002_bb0770","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3899\/jrheum.140543","article-title":"Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis","volume":"42","author":"Deng","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0775","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/ard.2006.052159","article-title":"Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome","volume":"66","author":"Gottenberg","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0780","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/ard.2004.030643","article-title":"Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0785","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10067-016-3437-0","article-title":"The significance and predictive value of free light chains in the urine of patients with chronic inflammatory rheumatic disease","volume":"35","author":"Bramlage","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0790","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3899\/jrheum.130905","article-title":"Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis","volume":"41","author":"Scarsi","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0795","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/ard.2009.126441","article-title":"Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity","volume":"69","author":"Kormelink","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0800","doi-asserted-by":"crossref","first-page":"9646209","DOI":"10.1155\/2018\/9646209","article-title":"Serological immunoglobulin-free light chain profile in myasthenia gravis patients","volume":"2018","author":"Basile","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/bs.acc.2021.08.002_bb0805","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific\u2014but not Total\u2014IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0810","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/NXI.0000000000000831","article-title":"High \u03ba free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis","volume":"7","author":"Wilf-Yarkoni","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/bs.acc.2021.08.002_bb0815","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1346-8138.2009.00763.x","article-title":"B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis","volume":"37","author":"Hasegawa","year":"2010","journal-title":"J. Dermatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0820","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: a possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/bs.acc.2021.08.002_bb0825","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jclinpath-2017-204656","article-title":"Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu","volume":"71","author":"Bosello","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0830","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","article-title":"Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity","volume":"13","author":"Lanteri","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/bs.acc.2021.08.002_bb0835","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/rheumatology\/key180","article-title":"Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sj\u00f6gren's syndrome","volume":"57","author":"Verstappen","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/bs.acc.2021.08.002_bb0840","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/annrheumdis-2015-208504","article-title":"EULAR Sj\u00f6gren Task Force, Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies","volume":"75","author":"Seror","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0845","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren's task force, EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0850","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.39315","article-title":"CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sj\u00f6gren's syndrome","volume":"67","author":"Nocturne","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0855","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/1756-185X.12965","article-title":"Diagnostic accuracy of salivary and serum-free light chain assays in primary Sj\u00f6gren's syndrome: a pilot study","volume":"20","author":"Sandhya","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0860","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0002-9343(80)90215-6","article-title":"Non-IgM monoclonal gammopathy in patients with Sj\u00f6gren's syndrome","volume":"68","author":"Sugai","year":"1980","journal-title":"Am. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0865","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.semarthrit.2012.07.003","article-title":"The role of ectopic germinal centers in the immunopathology of primary Sj\u00f6gren's syndrome: a systematic review","volume":"42","author":"Risselada","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/bs.acc.2021.08.002_bb0870","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1111\/liv.12829","article-title":"Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment","volume":"35","author":"Basile","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/bs.acc.2021.08.002_bb0875","doi-asserted-by":"crossref","first-page":"112687","DOI":"10.1016\/j.jim.2019.112687","article-title":"Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia","volume":"476","author":"Basile","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/bs.acc.2021.08.002_bb0880","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/biof.1485","article-title":"Serological profile of asymptomatic HCV positive patients with low level of cryoglobulins","volume":"45","author":"Basile","year":"2019","journal-title":"Biofactors"},{"key":"10.1016\/bs.acc.2021.08.002_bb0885","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bjid.2014.07.007","article-title":"Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia","volume":"18","author":"Oliveira","year":"2014","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0890","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3748\/wjg.v13.i17.2467","article-title":"Hepatitis C virus-related lymphoproliferative disorders: an overview","volume":"13","author":"Zignego","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0895","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/IJGM.S37580","article-title":"Hepatitis C virus infection and autoimmune diseases","volume":"5","author":"Paroli","year":"2012","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0900","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hep.26117","article-title":"B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia","volume":"58","author":"Sansonno","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/bs.acc.2021.08.002_bb0905","first-page":"320","article-title":"The impact of hepatitis viruses on chronic lymphoproliferative disorders--preliminary results","volume":"3","author":"Vladareanu","year":"2010","journal-title":"J. Med. Life"},{"key":"10.1016\/bs.acc.2021.08.002_bb0910","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/bs.acc.2021.08.002_bb0915","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.dld.2018.03.028","article-title":"Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients","volume":"50","author":"Basile","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0920","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","article-title":"Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias","volume":"165","author":"Monti","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0925","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/bs.acc.2021.08.002_bb0930","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/ard.2007.086488","article-title":"Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders","volume":"68","author":"Terrier","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/bs.acc.2021.08.002_bb0935","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/bab.1929","article-title":"Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia","volume":"68","author":"Basile","year":"2020","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/bs.acc.2021.08.002_bb0940","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/bjc.2014.121","article-title":"Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma","volume":"110","author":"Teng","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2021.08.002_bb0945","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.dld.2016.05.013","article-title":"Autoimmunity and lymphoproliferation markers in na\u00efve HCV-RNA positive patients without clinical evidences of autoimmune\/lymphoproliferative disorders","volume":"48","author":"Gulli","year":"2016","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/bs.acc.2021.08.002_bb0950","first-page":"1","article-title":"Solving the mystery of HBV related mixed cryoglobulinemia: potential biomarkers of disease progression","volume":"keab157","author":"Pocino","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/bs.acc.2021.08.002_bb0955","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1093\/hmg\/ddn246","article-title":"Autoimmune diseases: insights from genome-wide association studies","volume":"17","author":"Lettre","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.acc.2021.08.002_bb0960","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.imlet.2017.07.004","article-title":"Overview of immune abnormalities in lysosomal storage disorders","volume":"188","author":"Rigante","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/bs.acc.2021.08.002_bb0965","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/bs.acc.2021.08.002_bb0970","doi-asserted-by":"crossref","first-page":"e12977","DOI":"10.1111\/sji.12977","article-title":"COVID-19 and hepatic involvement: the liver as a main actor of the pandemic novel","volume":"93","author":"Napodano","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0975","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"China Medical Treatment Expert Group for Covid-19, clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2021.08.002_bb0980","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.acc.2021.08.002_bb0985","article-title":"Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19","author":"Dogan","year":"2020","journal-title":"Allerg. Immunol."},{"key":"10.1016\/bs.acc.2021.08.002_bb0990","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.beem.2020.101412","article-title":"ASIA syndrome and endocrine autoimmune disorders","volume":"34","author":"Bragazzi","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2021.08.002_bb0995","doi-asserted-by":"crossref","first-page":"102695","DOI":"10.1016\/j.autrev.2020.102695","article-title":"SARS-CoV-2, the autoimmune virus","volume":"19","author":"Halpert","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/bs.acc.2021.08.002_bb1000","series-title":"Advances in Clinical Chemistry","article-title":"Cryoglobulins: identification, classification, and novel biomarkers of mysterious proteins","author":"Napodano","year":"2020"},{"key":"10.1016\/bs.acc.2021.08.002_bb1005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.mayocp.2012.03.009","article-title":"Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/bs.acc.2021.08.002_bb1010","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/bs.acc.2021.08.002_bb1015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-020-0451-z","article-title":"COVID-19 revisiting inflammatory pathways of arthritis","volume":"16","author":"Schett","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/bs.acc.2021.08.002_bb1020","doi-asserted-by":"crossref","first-page":"102506","DOI":"10.1016\/j.jaut.2020.102506","article-title":"Autoinflammatory and autoimmune conditions at the crossroad of COVID-19","volume":"114","author":"Rodr\u00edguez","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/bs.acc.2021.08.002_bb1025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242321000639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242321000639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:05:07Z","timestamp":1753344307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242321000639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323988490"],"references-count":204,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2021.08.002","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}